Fig 3. Anti-RSPO3 OMP-131R10 is a therapeutic agent for liver fibrosis.

A, Treatment scheme of OMP-131R10 in CCl₄ liver fibrosis model. B, Picro Sirius Red staining of normal and CCl₄ induced mouse livers treated with OMP-131R10. C, Quantification of Picro Sirius Red staining area and liver collagen content. D, Quantification of liver collagen content. E, Immunohistochemistry analysis of α-SMA in the livers of normal and CCl₄ induced mouse livers treated with OMP-131R10. F, Quantification of α-SMA staining area. G, RT-PCR of Axin2. Liver fibrosis was induced by CCl₄ injection three times weekly for 6 weeks. The mice were treated from day 1 with OMP-131R10 at 25 mg/kg once a week (n = 10 animals per group except mineral oil control n = 4). Liver fibrosis was induced by CCl₄ injection three times weekly for 6 weeks. For prophylactic treatment mice were treated from Day 1 with OMP-131R10 at 25mg/kg once a week (n = 10 animals per group except mineral oil control n = 7). For therapeutic treatment mice were treated from day 14 with OMP-131R10 at 2, 6.25, and 20 mg/kg once every two weeks. At week 6, the study was terminated. Data is shown as mean ± SEM. Statistical comparison was done using one-way ANOVA with Dunnett’s multiple comparisons test using the Isotype as a control. * = p < 0.05, ** = p < 0.01, **** = p < 0.0001.